ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för BAY 41-2272. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

17 träffar

Bibliografisk träff 2018-02-20

Mechanistic Insights into the Activation of Soluble Guanylate Cyclase by Carbon Monoxide: A Multistep Mechanism Proposed for the BAY 41-2272 Induced Formation of 5-Coordinate CO-Heme.

Makino R, Obata Y, Tsubaki M, Iizuka T, Hamajima Y, Kato-Yamada Y, Mashima K, Shiro Y.

Biochemistry · research support, non-u.s. gov't; journal article · DOI 10.1021/acs.biochem.7b01240

Bibliografisk träff 2016-04-27

Soluble Guanylate Cyclase Modulators, BAY 41-2272 and BAY 60-2770, Inhibit Human and Rabbit Prostate Contractility.

Calmasini FB, Alexandre EC, Silva FH, De Nucci G, Antunes E, D'Ancona CA, Mónica FZ.

Urology · journal article · DOI 10.1016/j.urology.2016.04.023

Bibliografisk träff 2016-04-04

BAY 41-2272 Treatment Improves Acetylcholine-Induced Aortic Relaxation in L-NAME Hypertensive Rats.

Prawez S, Ahanger AA, Singh TU, Mishra SK, Sarkar SN, Kumar D.

Int J Angiol · research-article; journal article · DOI 10.1055/s-0036-1579625

Bibliografisk träff 2016-02-12

Antenatal BAY 41-2272 reduces pulmonary hypertension in the rabbit model of congenital diaphragmatic hernia.

Vuckovic A, Herber-Jonat S, Flemmer AW, Strizek B, Engels AC, Jani JC.

Am J Physiol Lung Cell Mol Physiol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1152/ajplung.00178.2015

Bibliografisk träff 2015-03-04

Beneficial effect of the soluble guanylyl cyclase stimulator BAY 41-2272 on impaired penile erection in db/db-/- type II diabetic and obese mice.

Nunes KP, Teixeira CE, Priviero FB, Toque HA, Webb RC.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.114.220970

Bibliografisk träff 2015-01-23

BAY 41-2272 activates host defence against local and disseminated Candida albicans infections.

Soeiro-Pereira PV, Falcai A, Kubo CA, Antunes E, Condino-Neto A.

Mem Inst Oswaldo Cruz · research support, non-u.s. gov't; research-article; journal article · DOI 10.1590/0074-02760140255

Bibliografisk träff 2014-09-17

Reduction of obstruction related bladder overactivity by the guanylyl cyclase modulators BAY 41-2272 and BAY 60-2770 alone or in combination with a phosphodiesterase type 5 inhibitor.

Füllhase C, Hennenberg M, Sandner P, Strittmatter F, Niedworok C, Bauer RM, Gratzke C, Soler R, Stief C, Andersson KE.

Neurourol Urodyn · journal article · DOI 10.1002/nau.22665

Bibliografisk träff 2013-11-11

BAY 41-2272, a soluble guanylate cyclase stimulator, relaxes isolated human ureter in a standardized in vitro model.

Miyaoka R, Mendes C, Schenka A, Gonzalez PG, de Nucci G, Antunes E, Monga M, Levi D'Ancona CA, Mónica FZ.

Urology · journal article · DOI 10.1016/j.urology.2013.09.005

Bibliografisk träff 2012-07-01

BAY 41-2272, a soluble guanylate cyclase agonist, activates human mononuclear phagocytes.

Soeiro-Pereira PV, Falcai A, Kubo CA, Oliveira-Júnior EB, Marques OC, Antunes E, Condino-Neto A.

Br J Pharmacol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1111/j.1476-5381.2011.01764.x

Bibliografisk träff 2012-05-22

Vas deferens smooth muscle responses to the nitric oxide-independent soluble guanylate cyclase stimulator BAY 41-2272.

da Silva FH, Claudino MA, Báu FR, Rojas-Moscoso JA, Mónica FZ, De Nucci G, Antunes E.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2012.05.009

Bibliografisk träff 2012-05-02

Mechanism of relaxation and interaction with nitric oxide of the soluble guanylate cyclase stimulator BAY 41-2272 in mouse gastric fundus and colon.

Cosyns SM, Lefebvre RA.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2012.04.049

Bibliografisk träff 2011-08-08

The soluble guanylate cyclase stimulator BAY 41-2272 inhibits vascular smooth muscle growth through the cAMP-dependent protein kinase and cGMP-dependent protein kinase pathways.

Joshi CN, Martin DN, Fox JC, Mendelev NN, Brown TA, Tulis DA.

J Pharmacol Exp Ther · research-article; journal article; research support, n.i.h., extramural · DOI 10.1124/jpet.111.183400

Bibliografisk träff 2010-12-01

Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats.

D'Ancona CA, Mónica FZ, Reges R, Cohen D, Silva FH, De Nucci G, Antunes E.

Einstein (Sao Paulo) · journal article · DOI 10.1590/s1679-45082010ao1789

Bibliografisk träff 2010-11-01

The anti-aggregating effect of BAY 41-2272, a stimulator of soluble guanylyl cyclase, requires the presence of nitric oxide.

Roger S, Badier-Commander C, Paysant J, Cordi A, Verbeuren TJ, Félétou M.

Br J Pharmacol · research-article; journal article · DOI 10.1111/j.1476-5381.2010.00943.x

Bibliografisk träff 2010-09-07

BAY 41-2272 inhibits the development of chronic hypoxic pulmonary hypertension in rats.

Thorsen LB, Eskildsen-Helmond Y, Zibrandtsen H, Stasch JP, Simonsen U, Laursen BE.

Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2010.08.032

Bibliografisk träff 2009-02-01

Antigrowth properties of BAY 41-2272 in vascular smooth muscle cells.

Mendelev NN, Williams VS, Tulis DA.

J Cardiovasc Pharmacol · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1097/fjc.0b013e31819715c4

Bibliografisk träff 2001-03-01

NO-independent regulatory site on soluble guanylate cyclase.

Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, Schröder H, Schroeder W, Stahl E, Steinke W, Straub A, Schramm M.

Nature · journal article · DOI 10.1038/35065611